Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

Sandoz Group AG

Novartis

Sandoz do Brasil

Sandoz Egypt

Sandoz Italia

Sandoz in Deutschland

Lek Pharmaceuticals

Sandoz India Pvt Ltd

Sandoz México

Sandoz Canada

Sandoz France

Sandoz Polska

Life at Sandoz

Sandoz Czech Republic

Sandoz Srbija

Sandoz Romania

Sandoz Hrvatska

Sandoz Nederland

Sandoz UK

Sandoz Australia & New Zealand

Sandoz Hungária

Sandoz Danmark

Sandoz Sverige

Sandoz is the global leader in generic and biosimilar medicines. 

Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance.

 We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars.

Sandoz

Today officially marks the start of a new era for Sandoz - a now independent, global leader in generic and biosimilar medicines.

We know that access to generic and biosimilar medicines allows healthcare systems across the globe to deliver high-quality, affordable treatments to people facing some of the most challenging diseases.

Off-patent therapies account for 80% of medicines used worldwide, a statistic that underscores why our Purpose, pioneering access for patients, is so important.

We believe that the world needs affordable, sustainable and high-quality healthcare now more than ever - and we will deliver on our purpose with renewed focus and ambition, working always with patients in mind.

Find out how we're shaping the future of healthcare: www.sandoz.com

#NewSandoz #Biosimilars #PioneeringAccess

Two months since becoming an independently listed medicines company and the energy is still high!

Every associate has contributed to this incredible moment and now we are well on our way to shaping our own future and bringing affordable medicines to millions.

Join Naoki Ito and our colleagues across the world in making an impact on human health: https://lnkd.in/eTcSpcQR
 
#SandozLife #Sandoz #PharmaJobs

We’ve wrapped up another successful Sandoz Research & Development (SRDD) days! 🙌

We spent the past three days recognizing the hard work of our employees, as well as their scientific achievements, which enable Sandoz to achieve its purpose of pioneering access to life-changing medicines for patients.

R&D days is all about sharing best practices, networking, learning from each other, and celebrating together. This is one of the ways we are creating a best-in-class experience for our employees as part of our commitment to accelerate their professional growth. To find out more about our supportive culture and our opportunities – visit our careers page: https://lnkd.in/eAJa7x8W

#SandozLife #CompanyCulture #WorkplaceCulture

Biosimilars have been available in Japan since 2009. So, why does biosimilar uptake lag behind other key markets globally and what can we learn from Europe's mature and well-developed biosimilar industry to improve the situation in Japan?🌎

Last week, we sponsored a panel discussion with Nikkei Business Publications, where Peter Stenico, Global Head Biosimilars and Country President Austria, joined leading Japanese public health and policy experts to discuss solutions for increased biosimilar adoption in Japan.

The discussions yielded useful insights into what has helped drive successful biosimilar adoption in Europe to date. Continuing to review and adopt approaches and policies that have contributed to strong uptake in other markets will be vital in supporting expanded access to biosimilars in Japan in the future.

We remain committed to driving conversations that support increased awareness about the potential and global uptake of biosimilars, so that patients and healthcare systems across the world can access these potentially life-changing medicines.💊

A huge thanks to everyone who contributed to this engaging discussion and to those who joined to watch live!

#PioneeringAccess #Biosimilars

Success in generics and biosimilars is not just about developing and manufacturing affordable, high-quality medicines. It’s essential to understand patient needs and perspectives. That’s why we involve the perspectives of the patient community in our work at Sandoz to pioneer access for patients.

Last week, our Global Director, Patient Communications and Engagement Izlen Toker spoke at the Patient Engagement Conference in Amsterdam about authentic patient advocacy and Sandoz’ approach to patient engagement.

Follow us to learn more about our commitment to working with patients in mind.
 
#PatientAdvocacy #WithPatientsInMind #Sandoz

Martin Schiestl, Global Head Regulatory Affairs Policy at Sandoz, has been recognized within the Contribution category at this year’s TOPRA - The Organisation for Professionals in Regulatory Affairs Awards for Regulatory Excellence! 🏆

This prestigious award highlights regulatory affairs professionals who have consistently demonstrated exceptional dedication and expertise over the past three years.

Martin's achievements are truly remarkable, reflecting a high level of regulatory affairs expertise, a commitment to driving more consistent patient access to medicines, and the ambition to identify biosimilar regulatory pathways. With almost three decades of experience, his role as a mentor to colleagues, coupled with his commitment to the improvement of regulatory affairs, is inspiring. Congratulations Martin for this well-deserved win! 🌟

#RegAwards23 #RegulatoryExcellence

As the global leader in off-patent medicines, we contribute to keeping healthcare systems sustainable and ensuring patients can afford the treatment they need, where and when they need it.

Access to care is one of our biggest concerns as a company. We work tirelessly to ensure high-quality treatments are readily available not only to patients, but also healthcare systems, globally.

Read more about how we continue to pioneer access: https://lnkd.in/eYvdw5rM

#PioneeringAccess #HealthEquity #Biosimilars

At Sandoz, diversity, equity and inclusion are at the heart of all we do.

We pride ourselves in ensuring our colleagues feel valued, respected and heard - so that everyone can be their authentic selves!

Click to learn more: https://lnkd.in/en3jcUGj

#SandozLife #WorkplaceCulture #CompanyCulture #Careers

Biosimilars allow patients worldwide to enjoy a better quality of life. Join #GlobalBiosimilarsWeek to get an insight into the opportunities biosimilar medicines can provide: https://lnkd.in/ewKrhd6z

We believe that being the global leader in generic and biosimilar medicines comes with an added layer of responsibility around manufacturing, access and use of antibiotics.

We want to make a positive change for both healthcare systems and patients globally - and our work against antimicrobial resistance shows just this: 
👉We produce 50+ medicines in generic antibiotics serving more than 200 million patients per year
👉We have a leading global program to combat AMR, taking a balanced, cross-sector approach

Our goal is simple: we want to ensure patients continue to receive the medicine they need, when and where they need it. Learn more about how we aim to achieve it: https://lnkd.in/eYvdw5rM

#AMR #AntimicrobialResistance #Biosimilars

	Dec '20	Dec '21	Dec '22	Dec '23
average inventory		1.95B -		2.12B -
average payables		878.74M -		1.18B -
average receivables		2.81B -		2.93B -
book value per share	15.82 -	17.24 8.93%	0.00 100.00%	16.87 9,427,931.80%
capex per share	-0.72 -	-0.89 23.38%		-1.32 -
capex to depreciation	-0.48 -	-0.85 79.51%		-1.20 -
capex to operating cash flow	-0.30 -	-0.31 2.72%		-1.75 -
capex to revenue	-0.03 -	-0.04 26.76%		-0.06 -
cash per share	0.08 -	0.08 5.72%	0.00 99.73%	2.16 932,856.92%
days of inventory on hand	155.38 -	143.67 7.53%		170.45 -
days payables outstanding	62.35 -	72.62 16.48%		100.57 -
days sales outstanding	106.38 -	123.96 16.53%		107.20 -
debt to assets	0.01 -	0.01 3.79%		0.22 -
debt to equity	0.03 -	0.03 3.99%		0.50 -
dividend yield
earnings yield	0.03 -	0.07 91.44%	-0.00 100.00%	0.01 329,922.03%
enterprise value	12.98B -	12.96B 0.13%	12.71B 1.91%	14.58B 14.67%
enterprise value over ebitda	6.52 -	7.10 8.84%	-565.08K 7,963,498.17%	9.26 100.00%
ev to operating cash flow	12.59 -	10.47 16.85%		44.82 -
ev to sales	1.44 -	1.47 2.61%		1.63 -
free cash flow per share	1.67 -	1.99 18.71%		-0.56 -
free cash flow yield	0.06 -	0.07 18.71%		-0.02 -
graham net net	-13.89 -	-12.43 10.57%	0.00 100.00%	-11.67 6,518,474.33%
graham number	18.93 -	27.33 44.41%	0.00 100.00%	7.81 1,688,797.29%
income quality	2.38 -	1.49 37.26%		4.70 -
intangibles to total assets	0.44 -	0.44 0.80%	0 100%	0.39 Infinity%
interest coverage	19.04 -	22.52 18.29%		6.10 -
interest debt per share	0.59 -	0.58 0.32%		8.84 -
inventory turnover	2.35 -	2.54 8.15%		2.14 -
invested capital	0.03 -	0.03 3.99%		0.50 -
market cap	12.71B -	12.71B 0%	12.71B 0%	11.67B 8.23%
net current asset value	-4.05B -	-3.48B 14.16%	77.14K 100.00%	-2.70B 3,495,927.79%
net debt to ebitda	0.13 -	0.14 2.19%	4.44 3,175.87%	1.85 58.40%
net income per share	1.01 -	1.93 91.44%	-0.00 100.00%	0.16 302,641.84%
operating cash flow per share	2.39 -	2.87 20.12%		0.75 -
payables turnover	5.85 -	5.03 14.15%		3.63 -
receivables turnover	3.43 -	2.94 14.18%		3.40 -
research and ddevelopement to revenue	0.09 -	0.09 4.43%		0.09 -
return on tangible assets	0.05 -	0.09 88.81%	-0.23 347.38%	0.01 103.04%
revenue per share	20.96 -	20.40 2.66%		20.73 -
roe	0.06 -	0.11 75.75%	-0.30 365.20%	0.01 103.21%
roic	0.12 -	0.12 0.18%	-0.30 339.06%	0.06 120.59%
sales general and administrative to revenue
shareholders equity per share	15.82 -	17.24 8.93%	0.00 100.00%	16.87 9,427,931.80%
stock based compensation to revenue	-0.15 -	-0.08 45.62%		-0.14 -
tangible asset value	-176.79M -	437.35M 347.39%	77.14K 99.98%	896.36M 1,161,902.68%
tangible book value per share	-0.41 -	1.01 347.39%	0.00 99.98%	2.08 1,161,363.72%
working capital	-3.10B -	-2.55B 17.75%	77.14K 100.00%	1.58B 2,044,588.29%

SDZ

COM:SANDOZ

Sandoz Group AG

Last Close

40.60

25/11 09:25

Market Cap

15.04B

Beta: -

Volume Today

91.56K

Avg: -

Preview